The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12625000906459
Ethics application status
Approved
Date submitted
22/07/2025
Date registered
20/08/2025
Date last updated
20/08/2025
Date data sharing statement initially provided
20/08/2025
Type of registration
Retrospectively registered

Titles & IDs
Public title
Testing the feasibility, acceptability and impact of an online delivered stress management program for Australian with breast and colorectal cancer
Scientific title
Testing the feasibility, acceptability and impact of an online delivered stress management program for Australian with breast and colorectal cancer: a pilot study
Secondary ID [1] 314809 0
Nil known
Universal Trial Number (UTN)
U1111-1324-8582
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
breast cancer 338062 0
colorectal cancer 338063 0
Condition category
Condition code
Cancer 334355 334355 0 0
Breast
Cancer 334356 334356 0 0
Bowel - Back passage (rectum) or large bowel (colon)
Cancer 334357 334357 0 0
Bowel - Small bowel (duodenum and ileum)
Cancer 334358 334358 0 0
Bowel - Anal
Mental Health 334818 334818 0 0
Other mental health disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Cognitive Behavioural Stress Management (CBSM) intervention. Participants in the intervention group will attend 5 weekly, 100-minute sessions delivered online through Zoom. Each session will be divided into three segments: i) an initial discussion (20 minutes), ii) cognitive behavioural therapy (CBT) components (40 minutes), and iii) relaxation techniques (40 minutes). Each group will include 4-5 people. First session: stress definition, appraisal process explanation, and 7 groups of progressive muscle relaxation. Second session: Automatic thoughts, cognitive distortions, deep breathing, 4 groups of progressive muscle relaxation, and guided imagery "Beach Scene". Third session: coping strategies, softening, deep breathing, and guided imagery "Special Place Imagery". Fourth session: Interpersonal Support and anger management, progressive muscle relaxation, and guided imagery "Light imagery". Fifth session: assertiveness training and meditation.
After attending the first session, participants will have access to a website where information about the content of each week’s session is shared, as well as a recording to practice the relaxation technique learned during each session. Participants will be encouraged to practice between sessions to enhance the effectiveness of the relaxation techniques and reinforce these new skills. Participants are encouraged to practice at least one relaxation technique between sessions. Each practice session typically lasts around 20 minutes. However, engaging in this practice is entirely up to the participant; choosing not to do so will not result in exclusion from the program. Additionally, the program’s website provides supplementary materials (e.g., slide presentations) summarising the content discussed in each session. These resources are intended to support participants who may experience side effects from cancer treatment and, therefore, require more time to focus on specific topics. The use of these materials is optional and depends entirely on each participant’s preferences and needs.
The intervention is delivered by A.V., a PhD student who has received training and ongoing support from the developer of the CBSM program. As this is not a therapeutic program, the facilitator is not required to be a registered psychologist or psychotherapist.
Adherence to the intervention will be assessed through a combination of attendance records and engagement with program materials. Specifically, the facilitator will record participants' attendance at each of the five weekly online group sessions. If a participant is unable to attend a session, they will be offered a shorter individual session to review the content they missed. This approach is intended to maintain intervention fidelity and support the participant in rejoining the group the following week. Usage data from the program website will be monitored at the beginning of each session to assess participants' interaction with the intervention content. If a participant is not engaging with the materials as expected, the facilitator will follow up to discuss any barriers they may be experiencing and explore potential solutions to support their continued involvement
Intervention code [1] 331407 0
Treatment: Other
Comparator / control treatment
Participants assigned to the control group will be contacted via email at week 1 and week 3 of the intervention period and provided with contact details of support organisations they can contact (e.g., Cancer Council Victoria, Breast Cancer Network Australia, Bowel Cancer Australia). This strategy aims to keep control participants engaged in the study until the end of the CBSM intervention and to understand the role of a low-involvement approach on patients’ well-being. After completing the last survey (3 months after the end of the intervention) they will be able to access the study website to obtain information about the stress management intervention and practice the relaxation techniques.
Control group
Active

Outcomes
Primary outcome [1] 342047 0
Feasibility
Timepoint [1] 342047 0
Upon conclusion of the study
Primary outcome [2] 342455 0
Acceptability
Timepoint [2] 342455 0
Upon conclusion of the intervention—specifically, within the two weeks following the fifth session—interviews will be conducted.
Secondary outcome [1] 449413 0
Stress level
Timepoint [1] 449413 0
Baseline (pre-intervention), post-completion of 5-week intervention, and 3 months after the end of the 5-week intervention
Secondary outcome [2] 449414 0
Intervention's effects
Timepoint [2] 449414 0
Baseline (pre-intervention), post-completion of 5-week intervention, and 3 months after the end of the 5-week intervention
Secondary outcome [3] 449415 0
Anxiety
Timepoint [3] 449415 0
Baseline (pre-intervention), post-completion of 5-week intervention, and 3 months after the end of the 5-week intervention
Secondary outcome [4] 449416 0
Health related quality of life
Timepoint [4] 449416 0
Baseline (pre-intervention), post-completion of 5-week intervention, and 3 months after the end of the 5-week intervention
Secondary outcome [5] 449417 0
Coping Strategies
Timepoint [5] 449417 0
Baseline (pre-intervention), post-completion of 5-week intervention, and 3 months after the end of the 5-week intervention
Secondary outcome [6] 449418 0
Illness Perception
Timepoint [6] 449418 0
Baseline (pre-intervention), post-completion of 5-week intervention, and 3 months after the end of the 5-week intervention
Secondary outcome [7] 449419 0
Stress perception and management (this will be assessed as a composite outcome)
Timepoint [7] 449419 0
Baseline (pre-intervention), post-completion of 5-week intervention, and 3 months after the end of the 5-week intervention
Secondary outcome [8] 449420 0
Social support
Timepoint [8] 449420 0
Baseline (pre-intervention), post-completion of 5-week intervention, and 3 months after the end of the 5-week intervention
Secondary outcome [9] 450870 0
Depression
Timepoint [9] 450870 0
Baseline (pre-intervention), post-completion of 5-week intervention, and 3 months after the end of the 5-week intervention
Secondary outcome [10] 450872 0
Psychological Distress
Timepoint [10] 450872 0
Baseline (pre-intervention), post-completion of 5-week intervention, and 3 months after the end of the 5-week intervention

Eligibility
Key inclusion criteria
a) a diagnosis of breast or colorectal cancer (Stage I, II or III),
b) aged 18 years old or older,
c) currently receiving any cancer treatment (e.g., surgery, chemotherapy, radiotherapy, hormone therapy),
d) having access to an internet-connected device (e.g., computer, tablet PC),
e) capacity to consent to the study,
f) willing to participate in a 5-week group program and engage in program activities,
g) able to read and speak English.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
a) severe cognitive impairment, thus, unable to provide consent,
b) a previous history of cancer or multiple primary cancers,
c) recurrence of cancer,
d) receiving non-curative treatment.

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (computerised sequence generation). The allocation sequence was generated in a 4-block permutation by a blinded statistician prior to recruitment.
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Descriptive characteristics will be conducted. Frequencies will be used to assess uptake and retention rates, determining the feasibility of the intervention. Generalised estimating equations (GEE) will be used to examine the potential impact of the secondary outcomes – stress, anxiety and depressive symptoms, quality of life, coping skills, illness representation, sense of coherence, and social support. In these analyses, after including the main effects for group and time, the statistical significance of the interaction of time by group will be tested to explore the impact of the intervention. GEE will be conducted to test the effect of the intervention at the end of the intervention and then at the 3-month follow-up.

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 319366 0
University
Name [1] 319366 0
Deakin University
Country [1] 319366 0
Australia
Primary sponsor type
University
Name
Deakin University
Address
Country
Australia
Secondary sponsor category [1] 321861 0
None
Name [1] 321861 0
Address [1] 321861 0
Country [1] 321861 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 317942 0
Barwon Health HREC
Ethics committee address [1] 317942 0
Ethics committee country [1] 317942 0
Australia
Date submitted for ethics approval [1] 317942 0
22/03/2024
Approval date [1] 317942 0
08/08/2024
Ethics approval number [1] 317942 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 142634 0
Prof Victoria White
Address 142634 0
221 Burwood Highway, Burwood, Melbourne, VIC 3125
Country 142634 0
Australia
Phone 142634 0
+61 392468522
Fax 142634 0
Email 142634 0
Contact person for public queries
Name 142635 0
Victoria White
Address 142635 0
221 Burwood Highway, Burwood, Melbourne, VIC 3125
Country 142635 0
Australia
Phone 142635 0
+61 392468522
Fax 142635 0
Email 142635 0
Contact person for scientific queries
Name 142636 0
Victoria White
Address 142636 0
221 Burwood Highway, Burwood, Melbourne, VIC 3125
Country 142636 0
Australia
Phone 142636 0
+61 392468522
Fax 142636 0
Email 142636 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Participants were informed in the plain language statement that their data would remain confidential, analysed in de-identified form, and reported only in combination with data from other participants. The nature of this study — a small-scale feasibility trial — means that individual-level data would not be scientifically informative on their own. Therefore, there is no plan to share individual participant data.





What supporting documents are/will be available?

TypeCitationLinkEmailOther DetailsAttachment
Ethical approval    080824_Letter.pdf


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.